Corpseed

CDSCO Clarifies Rule 4 Compounding Applications: Central vs State Authority, Eligibility, Process and Business Impact

Department: CDSCOAuthority: CDSCOPublish: Applicable: 21-07-2026Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.

Schedule a Call Back

IN +91

2,100+ CDSCO medical device assignments since 2018

Clients include Endolite India, Mankind Pharma, Ossur India, ADK Health Care, Credence Prosthetic India, V2U Physio Asia, International Electro Medical Company, Radimage Healthcare India, Istok New Hearing AID, Simpladent Implant Solutions, Starkey Laboratories India, Gentec Medical (12 of 1,100+ served since 2018).

A few more clients we've served in this industry
Pharma and healthcare
Endolite India · Mankind Pharma · Ossur India · ADK Health Care · Credence Prosthetic India · V2U Physio Asia · International Electro Medical Company · Radimage Healthcare India · Istok New Hearing AID · Simpladent Implant Solutions · Starkey Laboratories India · Gentec Medical · Cureesse Pharma · Hygiene Medicus · Nexus Surgical and Medicare
More clients
Meditronix Corporation · Nilkamal · Haesi GHL · GHL · Servotech Power Systems · Elektrocraft India · Happy Medicare · Anantaa Gsk Innovations · Cogmac Technologies · Aficionados Tech · Superceuticals · Truevis Technologies · 1008 Digital Health · BDS Services · Evoq Imaging Technologies · Premier Medical Systems and Devices · Riransa · Vitrag Infra Projects · Insta Biotech · Digital Acoustics · Artificial Learning Systems India · Nfilade Security Solutions · Humors Tech · K2O Consulting
See our CDSCO medical device service →

Summary

The Central Drugs Standard Control Organisation has issued an important clarification on compliance regarding applications filed under Rule 4 of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025.

According to the CDSCO circular dated 21 July 2026, it is also made clear that, to apply for compounding of any offence, the application must be made to the competent authority having jurisdiction over such offence. This clarification was needed because, in many cases, the Central Compounding Authority was receiving applications within the jurisdiction of the State/Union Territory Drug Control Administration.

This circular directly impacts all individuals and companies engaged in the manufacture, import, dealing in, distribution, wholesale dealing, marketing, and licensing of drugs and cosmetics, as per the Drugs and Cosmetics Act, 1940.

The point to note is that, simply because CDSCO is the central drug regulatory body, an application to compound the offence cannot be made to the Central Authority. First, the company in question needs to know who took the sample and which licensing authority has jurisdiction over the matter.

An application filed before an authority without jurisdiction may be returned or rejected. This can increase regulatory costs, delay case closure and prolong uncertainty around licences, commercial transactions and business operations.

Importantly, the July 2026 circular does not create a new compounding law. It clarifies how the existing Rule 4 filing mechanism must be used.

CDSCO Circular at a Glance

Particular Details
Issuing authority Central Drugs Standard Control Organisation
Administrative department Directorate General of Health Services, Government of India
Circular date 21 July 2026
CDSCO release date 22 July 2026
Subject Clarification regarding submission of applications under Rule 4
Applicable framework Drugs and Cosmetics (Compounding of Offences) Rules, 2025
Stakeholders covered Manufacturers, importers, distributors, licence holders and other applicants
Main requirement Application must be filed before the competent compounding authority having jurisdiction
Central jurisdiction Sample drawn by a CDSCO Drugs Inspector or offence concerning the Central Licensing Authority
State jurisdiction Sample drawn by a State/UT Drugs Inspector and offence falling under the State/UT Drugs Licensing Authority
Risk of filing before the wrong authority Application may be returned or rejected, requiring refiling before the competent authority

What Is Compounding of an Offence?

Compounding is an administrative procedure that allows certain offences to be handled without going through the entire criminal process, upon payment of the amount set by the concerned authorities and adherence to the stipulated conditions.

In practical terms, it allows an eligible company or individual to approach the designated compounding authority, disclose the facts of the case, submit the prescribed application and request that the offence be compounded.

The authority may examine the application, obtain a report from the relevant licensing or reporting authority, hear the applicant and decide whether the case should be compounded. If the application is accepted, the authority specifies the compounding amount and may grant immunity from prosecution subject to conditions.

Compounding should not be confused with:

  • Automatic payment of a regulatory penalty,
  • An out-of-court private settlement,
  • Withdrawal of every regulatory action against the applicant,
  • Cancellation of inspection findings,
  • Automatic protection of a drug or cosmetic licence, or
  • A general waiver covering all past or related violations.

It is a formal statutory proceeding available only for eligible offences and only with the competent authority's permission.

Is compounding available as a right?

No. Compounding of offences is not an absolute right of an individual. The application form for compounding of offences explicitly mentions that compounding cannot be claimed as a right by the applicant. The authority takes into account the type of offence, the applicant's disclosures, the applicant's cooperation in the case, relevant documentation, and the regulatory authority's report.

Background of the Compounding Framework

The Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 regulates the import, manufacture, distribution and sale of drugs and cosmetics in India. It establishes requirements for quality, safety, licensing, labelling, record-keeping, and enforcement for regulated businesses.

The Act works through the regulatory framework at both Central and State levels. The CDSCO and the Central Licensing Authority perform certain roles at the Central level, including those concerning important imports and products under central regulation. The State and UT Drug Control Authorities handle other roles.

This division of authority is one of the main reasons why businesses must carefully determine jurisdiction before filing a compounding application.

Section 32B of the Drugs and Cosmetics Act

Section 32B provides the statutory basis for compounding specified offences. It permits eligible offences to be compounded either before or after the institution of prosecution, subject to the statutory restrictions and prescribed procedure.

The section also provides that:

  • Only specified offences can be considered,
  • The Central Government, State Government or an authorised officer may undertake compounding,
  • The compounding amount cannot exceed the applicable statutory limit,
  • A subsequent offence is not compoundable,
  • Court permission may be required where the accused has been committed for trial or has been convicted, and an appeal is pending, and
  • Once an offence is validly compounded, further proceedings concerning that compounded offence are restricted in accordance with the Act.

The complete statutory eligibility conditions must be examined before preparing an application.

Jan Vishwas (Amendment of Provisions) Act, 2023

The Jan Vishwas (Amendment of Provisions) Act, 2023 was introduced to rationalise regulatory offences, support trust-based governance, and promote ease of doing business.

Among other amendments, it expanded the provisions referenced in Section 32B of the Drugs and Cosmetics Act. The relevant amendments became effective on 31 December 2024.

The objective was not to weaken drug-quality regulation. It was to create a structured method for resolving eligible regulatory contraventions while allowing serious public-health violations to continue under the stricter prosecution framework.

Drugs and Cosmetics (Compounding of Offences) Rules, 2025

The Ministry of Health and Family Welfare notified the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 through G.S.R. 259(E) dated 24 April 2025.

The Rules prescribe:

  • Appointment of compounding authorities,
  • Form and manner of application,
  • Information and documents to be submitted,
  • Procedure for obtaining the reporting authority's comments,
  • Decision-making process,
  • Payment of the compounding amount,
  • Grant of immunity from prosecution, and
  • Withdrawal of immunity in specified circumstances.
  • Appointment of the Central Compounding Authority

The Central Government appointed the Additional Director General of Health Services, who deals with CDSCO matters, as the Central Compounding Authority.

The appointment authorises the officer to exercise the Central Government's powers and functions in relation to the compounding of eligible offences. 

Legal and Regulatory Timeline

Date Regulatory development Business significance
11 August 2023 Jan Vishwas Act received presidential assent Introduced a wider decriminalisation and trust-based compliance framework
31 December 2024 Relevant Drugs and Cosmetics Act amendments became effective Expanded the statutory compounding framework
24 April 2025 G.S.R. 259(E) notified Compounding of Offences Rules became operational
1 August 2025 S.O. 3551(E) issued Central Compounding Authority was appointed
2025–2026 CDSCO issued guidance, procedural material and FAQs Application requirements and regulatory process were explained
21 July 2026 CDSCO jurisdiction clarification issued Correct Central-versus-State filing position was clarified
22 July 2026 Circular published on the CDSCO website Clarification became publicly available to regulated stakeholders

Why Did CDSCO Issue the 2026 Clarification?

Applications were being filed before the wrong authority

CDSCO observed that applications were being submitted to the Central Compounding Authority even when the sample had been drawn by a State or UT Drugs Inspector and the alleged offence fell under the jurisdiction of the State or UT Drugs Licensing Authority.

Such applications create a jurisdictional problem. An authority must have legal competence over the alleged offence before it can process and decide the request.

India follows a dual regulatory structure.

Drug and cosmetic regulation in India is divided between Central and State authorities. A company may hold different licences for manufacturing, importing, selling or distributing regulated products, with different authorities controlling different parts of the business.

A single company may therefore have:

  • State manufacturing licences,
  • Central import registrations,
  • Medical-device permissions,
  • Cosmetic import registrations,
  • Wholesale or sale licences, and
  • Multiple facilities operating across States.

This regulatory structure makes it unsafe to select the compounding authority only based on the applicant's registered office or corporate location.

Incorrect filing causes delay and additional cost.

When an application is submitted to the wrong authority, it may have to be returned, rejected, or resubmitted. The business may then face:

  • Duplicate professional and documentation expenses,
  • Additional regulatory communication,
  • Duplicate internal authorizations,
  • Extended resolution times for cases,
  • Uncertainty regarding prosecution, and
  • Increased pharmaceutical legal compliance costs.

For companies facing regulatory due diligence, investment, licence renewal or a business acquisition, an unresolved enforcement proceeding can also become a significant commercial concern.

Uniform implementation was required.

The circular creates a common principle for applicants and regulators: determine the authority connected with the sample, alleged offence and licensing jurisdiction before submitting the Rule 4 application.

What Has Changed?

The circular clarifies the filing forum for Rule 4 applications.

The following position must now be followed clearly:

  • A State or UT matter should be filed before the concerned State or UT Compounding Authority,
  • A matter arising from sampling by a CDSCO Drugs Inspector should be filed before the Central Compounding Authority,
  • A matter falling under the Central Licensing Authority should be filed before the Central Compounding Authority, and
  • An application filed before an authority without jurisdiction is liable to be returned or rejected.

The clarification places greater responsibility on applicants and their CDSCO compliance consultants to perform a jurisdiction assessment before filing.

What Has Not Changed?

The circular does not:

  • Introduce a new compounding law,
  • Replace the 2025 Rules,
  • Create a new prescribed application form,
  • Expand the statutory list of compoundable offences,
  • Make every drug, cosmetic or medical-device violation compoundable,
  • Establish a compounding amount that is universally applied,
  • Ensure acceptance of the application,
  • Offer automatic exemption from prosecution,
  • Discontinue the need for honest disclosure,
  • End the involvement of the reporting authority,
  • Establish a new process of appeal,
  • Automatic closure of other proceedings, or
  • Automatic protection of the licence from suspension or cancellation proceedings.

This is an important difference to make. The 2026 circular is a jurisdictional compliance notice, not a new compounding scheme.

Who Is Affected?

Drug manufacturers

The companies under inspection, test report, show cause notice, or investigation for prosecution shall ascertain whether a State Drugs Inspector or a CDSCO officer initiated the case.

Pharmaceutical importers

Issues related to import tend to be Central in nature. Nevertheless, firms should investigate whether the licence, officer, breach, and enforcing authority have Central jurisdiction.

Cosmetic manufacturers and importers

Firms in the cosmetic sector shall determine whether the violation issue falls under State or Central jurisdiction.

Medical-device and IVD businesses

Medical devices notified as drugs may fall within the wider Drugs and Cosmetics regulatory framework. However, eligibility for compounding and the appropriate authority must be assessed on a case-by-case basis, based on the specific offence and licensing facts.

Distributors, stockists and wholesalers

Distributors and wholesalers may face allegations relating to storage, sale, records, disclosure of the product source or distribution of non-compliant products. The relevant State or Central authority will depend on the facts of the proceeding.

Marketing companies and licence holders

Marketing authorisation holders and businesses that market products manufactured by third parties must review whether they are separately named or implicated in the case.

Directors and responsible officers

Section 32B refers to eligible offences committed by companies or their officers. Separate applications may be required for different persons or entities, depending on how the proceeding was initiated.

Which Offences Can Be Considered for Compounding?

Section 32B refers to specified provisions of the Drugs and Cosmetics Act. Their broad nature is set out below, but actual eligibility must be determined from the current statutory language, charge and facts.

Legal provision Broad subject Important eligibility consideration
Section 13(1)(b) Certain prohibited import contraventions not falling within the more serious category under Section 13(1)(a) Generally connected with Central import jurisdiction, but exact facts must be verified
Section 27(d) Drug-related contraventions not covered by the more serious categories in Sections 27(a), 27(b) or 27(c) Exact charge and statutory conditions require legal examination
Section 27A(ii) Certain cosmetic contraventions other than the more serious spurious or adulterated cosmetic category Central or State jurisdiction depends on licensing and enforcement facts
Section 28 Failure to disclose specified manufacturer or source particulars Authority depends on the inspector and underlying regulatory proceeding
Section 28A Failure to maintain prescribed records or furnish required information without reasonable cause Licensing and inspection jurisdiction must be examined

Just because a number exists in Section 32B does not imply that all cases filed under this section can be compounded. All statutory requirements need to be satisfied by the applicant.

Statutory limitations

A business needs to know whether:

  • The specific offence falls within Section 32B,
  • Compounding of such offences is possible through the statutory punishment scheme,
  • It is a first-time offence,
  • There is an issue of conviction or a subsequent offence,
  • Prosecution of the offence has begun,
  • The accused has been committed for trial,
  • Conviction has taken place, and an appeal is pending,
  • Permission from the court is needed,
  • There have been full and frank disclosures on the part of the applicant, and
  • Other proceedings exist under another statute.

Serious offences involving spurious, adulterated or harmful products should never be assumed to be compoundable without a detailed pharmaceutical regulatory and legal assessment.

Rule 4 Explained: Form and Manner of Application

Rule 4 governs how an application for compounding must be made.

When can the application be submitted?

An application may be made either before or after the institution of prosecution.

However, the stage of the case matters. If the accused has already been committed for trial, or has been convicted and an appeal is pending, court permission may be necessary under Section 32B.

Who can apply?

A company or individual involved in the manufacture, import, sale, distribution or another regulated activity may apply in respect of an eligible offence.

Where multiple entities or individuals are involved, each applicant may need to submit an individual application. A company should not assume that its application automatically covers its directors, responsible officers, marketers or distributors.

Which form must be used?

The application must be submitted in the prescribed form appended to the Rules, along with relevant supporting documents.

What must the applicant declare?

The applicant must:

  • Agree to pay the amount determined by the compounding authority,
  • Acknowledge that compounding cannot be demanded as a right,
  • Confirm that the information provided is true,
  • Confirm that no material fact has been suppressed,
  • Verify the authenticity of accompanying documents, and
  • Establish the signatory's authority and competence to submit the application.

How to Determine the Correct Compounding Authority

Correct jurisdiction is now the most important pre-filing step.

Step 1: Identify who drew the sample

Review the sampling documents and establish whether the sample was drawn by:

  • A Drugs Inspector appointed by a State or UT Government, or
  • A CDSCO Drugs Inspector.

The circular specifically links the competent authority to the authority that drew the sample.

Step 2: Identification of Licensing Authority

The applicant should find out whether the licence and regulated activities related to the alleged offence are governed by:

  • State/UT Drugs Licensing Authority or
  • Central Licensing Authority.

Step 3: Identification of Subject Matter of Alleged Offence

The applicant should consider whether the subject matter of the alleged offence relates to:

  • Manufacture,
  • Import,
  • Sale/Distribution,
  • Product Quality,
  • Labeling,
  • Disclosure of the manufacturer or source,
  • Licence conditions, or
  • Another regulated activity.

Step 4: Review the enforcement documents

The following documents can help establish jurisdiction:

  • Sample-drawing form,
  • Inspection report,
  • Test or analysis report,
  • Show-cause notice,
  • Seizure memo,
  • Complaint or charge sheet,
  • Manufacturing licence,
  • Import licence,
  • Registration certificate,
  • Correspondence with CDSCO or the State authority, and
  • Details of the officer who initiated the proceeding.

Step 5: Verify the designated authority

Businesses should confirm that the relevant Central or State compounding authority has been appointed and obtain the latest filing instructions.

If a State or UT process is unclear, the applicant should seek a written or professional assessment of jurisdiction. It should not automatically redirect the matter to the Central Authority.

Central vs State Jurisdiction Matrix

Regulatory situation Competent authority
Sample drawn by a State/UT Drugs Inspector and offence falls under State/UT Licensing Authority Concerned State/UT Compounding Authority
Sample drawn by a CDSCO Drugs Inspector Central Compounding Authority
Alleged offence concerns a Central Licensing Authority matter Central Compounding Authority
State officer drew the sample, and the matter is entirely State-licensed State/UT Compounding Authority
Case involves Central and State licences or multiple inspecting authorities Detailed jurisdiction assessment required before filing
Identity of the sample-drawing officer is unclear Review original sampling, inspection and enforcement records
Application has already been filed before an authority without jurisdiction It may be returned or rejected, the applicant may have to refile
Applicant’s head office is in one State but offence occurred elsewhere Jurisdiction should be based on the offence, inspector and licensing authority, not merely the head-office location

Application has already been filed before an authority without jurisdiction. It may be returned or rejected; the applicant may have to refile    

Effective Date and Implementation Requirements

The Compounding of Offences Rules were promulgated on 24 April 2025. The clarifications regarding the jurisdiction were released on 21 July 2026.

As the circular provides no future implementation date, firms planning to file new applications must strictly abide by the jurisdictional stance as clarified immediately.

Companies with applications already pending before an authority should review whether the chosen authority has jurisdiction. Where an application appears to have been filed incorrectly, the company should obtain professional advice before withdrawing, amending or refiling it.

Documents Required for a Rule 4 Compounding Application

The official CDSCO guidance contains the application checklist and the administrative process flow.

Document category Documents and information
Applicant information Name, registered address, communication address and contact details
Corporate authorisation Board resolution, power of attorney or authorisation of the signatory
Product details Product name, composition, manufacturer, importer and marketer information
Regulatory permissions Manufacturing licence, import licence, registration certificate and applicable approvals
Import documentation Import Export Code and relevant import records, where applicable
Quality documentation Manufacturer’s Certificate of Analysis or report from an NABL-accredited laboratory, where relevant
Sampling documents Applicable sample-drawing forms, including Form 17, COS-10 or MD-36
Test reports Applicable reports such as Form 13, Form 2, COS-14, COS-21, MD-31 or MD-32
Enforcement documents Inspection report, show-cause notice, seizure memo, charge sheet or complaint
Offence particulars Provisions allegedly contravened, date, location and brief facts
Case status Whether prosecution is contemplated, instituted, at trial or under appeal
Previous proceedings Details of earlier offences, convictions or regulatory proceedings
Other laws Details of proceedings concerning the same conduct under any other law
Applicant’s declaration Agreement to pay and acknowledgement that compounding is not a legal right
Verification Confirmation of truthfulness, completeness and non-suppression of facts

Step-by-Step Compliance Process

1. Examine the alleged offence

Identify the exact section invoked in the show-cause notice, complaint, test report, or prosecution document.

Do not describe the matter as compoundable until the current statutory provision and Section 32B conditions have been reviewed.

2. Determine first-offence status

Determine whether the company or the concerned officer was previously convicted of the same offence or any other relevant offence.

The offence is not compoundable as per Section 32B.

3. Find out at what stage the proceeding is at

Ascertain if the proceeding is at:

The stage of filing of prosecution,

A complaint has been lodged,

Committed to trial,

A trial is ongoing, or an appeal is pending.

This determines whether additional court permission may be necessary.

4. Conduct a jurisdiction assessment

Identify:

  • Who selected the sample,
  • Who served the notice,
  • By which body was the licence issued,
  • Where the alleged offence was committed,
  • Is it a Central or State issue, and
  • Which compounding authority is legally empowered to do so.

5. Prepare the prescribed form

Complete every applicable field. Where a field is not applicable, clearly mark it as not applicable instead of leaving it unexplained.

6. Compile supporting documents

It is required to gather and organise all documents which include:

  • Licenses,
  • Approvals for products,
  • Laboratory papers,
  • Sampling papers,
  • Inspection papers,
  • Show-cause notices,
  • Legal papers, and
  • Authorisations by the corporation.

7. Prepare the factual statement

The factual submission should explain:

  • What happened,
  • When and where it happened,
  • The applicant's role,
  • The alleged violation,
  • The present status of proceedings,
  • Corrective action taken,
  • Preventive measures implemented, and
  • Why the application satisfies the statutory conditions.

The statement should be transparent and consistent with every document already submitted to the regulator or court.

8. Submit before the competent authority

Follow the latest filing mode prescribed by the concerned Central or State authority.

The filing instructions applicable to the Central Compounding Authority should not automatically be used for a State application.

9. Respond to regulatory queries

The authority may request explanations, documents or additional information. Responses should be accurate, complete and filed within the allowed period.

10. Prepare for the hearing

If a hearing is scheduled, the applicant should prepare:

  • A concise chronology,
  • Legal eligibility submissions,
  • Technical and quality explanations,
  • Corrective-action evidence,
  • Licence and inspection records, and
  • Responses to the reporting authority's observations.

11. Comply with the order

If the application is allowed, the applicant must pay the specified amount within the prescribed time and furnish proof of payment.

12. Monitor immunity conditions

The applicant should maintain a written record of every condition and track continuing compliance.

What Happens After Filing?

Once an application is received, the compounding authority seeks a report from the reporting authority having jurisdiction over the alleged offence.

The reporting authority is generally the relevant licensing authority, the Central Licensing Authority, or the Central Licence Approving Authority connected with the place where the offence was committed or allegedly committed.

After reviewing the application and report, the compounding authority may:

  • Allow the application,
  • Specify the compounding amount,
  • Grant immunity subject to conditions, or
  • Reject the application.

Before rejecting an application, the applicant must be given a hearing, and the grounds for rejection must be recorded.

Every order must be communicated to the applicant.

Procedural Timelines

Stage Responsible person or authority Timeline
Submission of application Applicant Before or after institution of prosecution
Calling for factual report Compounding Authority After receiving the application
Submission of report Reporting Authority Generally within one month, subject to permitted extension
Internal request to the relevant CDSCO office in a Central case Reporting Authority CDSCO guidance describes an internal five-day step
Internal report by the concerned zonal, sub-zonal or port office Concerned CDSCO office CDSCO guidance describes an internal ten-day step
Opportunity of hearing Compounding Authority Before rejection
Payment of compounding amount Applicant Within 30 days of receiving the order
Submission of payment proof Applicant Within the prescribed payment period
Continuing compliance Applicant Throughout the period of any conditions imposed

The compounding authority may extend the one-month reporting period. Businesses should therefore treat it as a statutory procedural benchmark, not a guaranteed final-disposal date.

Grounds for Return, Rejection or Delay

A Rule 4 application may face difficulty because of:

  • Filing before an authority without jurisdiction,
  • Incorrect identification of the sample-drawing inspector,
  • Failure to establish statutory eligibility,
  • Incomplete prescribed form,
  • Missing licences or product approvals,
  • Inconsistent dates or factual submissions,
  • Failure to disclose previous proceedings,
  • Missing prosecution or court documents,
  • Absence of proper corporate authorisation,
  • Joint filing where individual applications are required,
  • Suppression of material information,
  • False or misleading evidence,
  • Failure to answer regulatory queries,
  • Lack of supporting corrective-action records, or
  • Failure to obtain court permission where required.

A jurisdictional return should be distinguished from a rejection on the merits. If an application is returned because it was submitted to the wrong authority, that does not necessarily mean the underlying offence is ineligible. However, the applicant must still correct the filing and independently establish eligibility before the proper authority.

Compounding Amount and Payment Obligations

The compounding authority determines the amount after considering the application, case facts, and reporting authority's comments.

Businesses should not assume there is a single standard CDSCO compounding fee applicable to every case. The amount depends on the legal provision and facts, subject to the statutory ceiling.

Once an order allowing compounding is received, the applicant must generally:

  • Pay the specified amount within 30 days,
  • Credit the amount as directed,
  • Preserve the payment record, and
  • Furnish proof to the compounding authority.

The amount is generally non-refundable. The Rules recognise a limited exception where the court rejects the grant of immunity.

Failure to pay within the required period can result in withdrawal of immunity and continuation of prosecution.

Immunity from Prosecution

The compounding authority may grant immunity when satisfied that the applicant has:

  • Cooperated during the proceedings,
  • Made a full and true disclosure,
  • Submitted the required information, and
  • Complied with the conditions of the compounding order.
  • Immunity is case-specific. It does not necessarily protect the applicant from:
  • Unrelated offences,
  • Proceedings under another law,
  • Future contraventions,
  • Separate licence suspension or cancellation,
  • Product recall or corrective action,
  • Civil or contractual claims, or
  • Action arising from information that was concealed.

Withdrawal of immunity

Immunity may be withdrawn where the applicant:

  • Fails to pay the compounding amount,
  • Fails to comply with an imposed condition,
  • Conceals a material fact,
  • Gives false evidence, or
  • Makes an incomplete or misleading disclosure.

Once immunity is withdrawn, the applicant may be prosecuted as if the immunity had never been granted.

This makes document accuracy and legal review critical. A poorly prepared application can create greater risk if it contains inconsistent statements or incomplete disclosures.

Impact on Pharmaceutical, Cosmetic and Medical-Device Businesses

Business area Compliance impact
Regulatory strategy Jurisdiction assessment becomes a mandatory practical pre-filing exercise.
Application cost Correct filing can prevent duplicate professional and documentation expenses.
Case timelines Wrong filing can result in return, rejection, and refiling delays.
Legal exposure Compounding remains discretionary and subject to statutory eligibility.
Licence management Separate licensing proceedings may continue despite compounding.
Documentation Sampling, inspection, testing and prosecution records must be traceable
Management time Legal, regulatory, quality and senior-management teams must coordinate
Transaction readiness Pending proceedings may affect investor, lender or acquisition due diligence.
Business reputation Transparent and timely resolution may demonstrate responsible compliance conduct.
Governance Directors and responsible officers need accurate visibility over pending regulatory cases.

Financial and Commercial Consequences of Incorrect Filing

The cost of filing before the wrong authority is not limited to the need for a fresh set of documents.

Businesses may incur:

  • Additional legal and professional fees,
  • Further legal and professional fees,
  • Re-filing costs for duplicate compounding application,
  • Costs for regulatory consultants,
  • Notarization, attestation, and authorization costs,
  • Time of senior management,
  • Technical evaluation of the application by quality and regulatory departments,
  • Hearing costs and travel,
  • Delay in conclusion of prosecution case,
  • Lengthy period for disclosing information in the due diligence process of investment, and
  • Reputation risk with regulators and investors.

A timely jurisdiction assessment by a qualified pharma regulatory consultant in India may therefore reduce the total cost of the proceeding.

How Businesses Can Achieve Compliance

Immediate compliance actions

Companies with pending cases involving regulatory authorities should:

  • Examine all ongoing inspection findings,
  • Identify all show cause notices that have been issued,
  • Determine the section that deals with the alleged offence under Section 32B,
  • Find out whether the case is a first offence,
  • Identify the sampler,
  • Determine which authority issued the license in question,
  • Determine whether it is a matter for Central or State authorities,
  • Determine the designated compounding authority,
  • Identify testing and sampling records,
  • Review the form prescribed,
  • Establish where the prosecution is at,
  • Seek legal opinion on court permission (if required), and
  • Create a consistent application.

Long-term compliance controls

Businesses should establish:

  • Regulatory case file registry,
  • License to authority map,
  • Jurisdiction matrix for each location,
  • Sample and inspection documents,
  • Prosecution status monitoring,
  • Previous conviction declaration process,
  • Pre-filing legal assessment,
  • Records of corrective and preventative actions,
  • Hearing response process,
  • Conditions for payment and immunity, and
  • Drug license and regulation compliance audits.

Common Mistakes Businesses Must Avoid

Treating every offence as compoundable

Only specified offences can be considered. A legal eligibility review must come before application preparation.

Filing every case before CDSCO

CDSCO is the national regulatory organisation, but the Central Compounding Authority does not automatically have jurisdiction over State matters.

Relying on the company's registered office

The location of the head office is not the sole deciding factor. The inspector, offence, licence and regulatory subject matter must be examined.

Ignoring the sample-drawing documents

The circular gives significant importance to the authority that drew the sample.

Confusing the reporting authority with the compounding authority

The reporting authority provides the factual regulatory report. The compounding authority decides the application.

Previous proceedings suppression

Failure to disclose previous offences, prosecutions, or regulatory proceedings will affect eligibility and immunity.

Inconsistency in facts used

There should be consistency in the facts provided in the Rule 4 application, show-cause responses, licensing applications, lab reports, and pleadings.

Thinking that payments settle all matters

Payment will not suffice. Evidence must be furnished, compliance undertaken, and separate regulatory proceedings might still be needed.

Missing the payment deadline

Failure to pay within 30 days may result in the withdrawal of immunity.

Benefits for Businesses

The compounding process can provide substantial benefits in certain cases:

  • Resolving the issue faster than through lengthy prosecution,
  • Lowering costs incurred on litigation,
  • Lessening the management burden,
  • Ensuring more certainty over the ongoing proceeding,
  • Chance to exhibit remediation measures,
  • Enhancing cooperation with regulators,
  • Improving preparation for due diligence with respect to regulation,
  • Eliminating disruption arising from past technical offenses,
  • Formal resolution of the compounded offense, and
  • Optimization of judicial/regulatory resources.

These benefits are subject to approval. No applicant should market or treat compounding as guaranteed immunity.

Is the Clarification a Right Decision or an Additional Burden?

The circular is broadly a positive administrative clarification because it addresses a genuine filing problem. It can reduce misdirected applications and help Central and State authorities process cases within their respective jurisdictions.

However, it also requires businesses to undertake more careful due diligence before filing.

Positive outcome Practical concern
Clarifies the appropriate filing authority Applicants must perform a detailed jurisdiction assessment.
Reduces misdirected applications Mixed Central-State cases may remain complex.
Supports faster case processing State-level procedures may not be identical.
Promotes uniform regulatory implementation Incorrect classification may still result in a return or rejection.
Supports ease of doing business Professional legal and regulatory assistance may be required.
Creates a structured alternative for eligible offences Compounding remains discretionary
Encourages corrective compliance Immunity may be withdrawn for non-compliance

The clarification should not be viewed as a new burden in itself. The underlying responsibility to file before the competent authority already existed. The circular makes that responsibility explicit and warns applicants about the consequences of incorrect filing.

From a policy perspective, it is the right decision because it improves administrative clarity without diluting enforcement against serious violations.

Business Opportunities Created

The clarification is likely to increase demand for specialised regulatory and compliance support.

Regulatory jurisdiction assessment

Pharmaceutical, cosmetic, and medical-device businesses will need professional assistance to determine whether their matters fall under Central or State jurisdiction.

Rule 4 application preparation

Demand may grow for compounding application filing services, document review, and structured factual submissions.

Pharmaceutical compliance audits

Organizations could carry out preventive audits to detect:

Gaps in licences,

Documentation failures,

Labelling problems,

Risk of inspection,

Quality problems documentation, and

Compoundable past cases.

Regulatory case-management services

Multi-State manufacturers and distributors may require centralised monitoring of notices, hearings, prosecutions, payment deadlines and immunity conditions.

Corrective and preventive action support

Consultants in quality and regulation can help organizations establish appropriate corrective actions to improve their application and prevent future violations.

Regulatory compliance technology

The circular creates demand for digital tools that track:

Licenses,

Inspecting bodies,

Samples of documents,

Regulatory cases,

Judicial proceedings,

Application process, and

Deadline for payments.

Transactional regulatory due diligence

Investors, acquirers and lenders may seek specialised pharmaceutical regulatory due diligence to assess whether pending violations are eligible for compounding and whether they could affect a business's value.

How Can Corpseed Help?

Preparing a Rule 4 application requires more than completing a form. The applicant must establish eligibility, identify the correct authority, organise technical records and maintain consistency across regulatory and legal documents.

Corpseed can support pharmaceutical, cosmetic and medical-device businesses through a structured compliance approach.

Preliminary eligibility assessment

Corpseed can assist with:

  • Reviewing the alleged offence,
  • Identification of relevant statute,
  • Verification of applicability of Section 32B,
  • Assessment of first-time offence,
  • Assessment of the stage of prosecution, and
  • Identification of issues needing legal expertise/court approval.

Central-versus-State jurisdiction assessment

Our regulatory-support process can help businesses:

  • Identify the sample drawing inspector,
  • Evaluate the sample and inspection papers,
  • Match the license to its issuing authority,
  • Determine whether the matter falls under Central or State control, and
  • Identify the appropriate compounding authority.

This service can reduce the risk of an application being returned or rejected for want of jurisdiction.

Documentation and application support

Corpseed can provide support in:

  • Rule 4 documents checklist,
  • Check of the application form,
  • Corporate authorization documents,
  • License and registration documentation,
  • Samples and testing documentation,
  • Show cause and prosecution documents,
  • Chronology preparation,
  • Records of corrective actions, and
  • Document indexing and organization.

Filing and regulatory coordination

Subject to the applicable procedure and professional scope, Corpseed can assist with:

  • Coordinate filing before the appropriate authority,
  • Regulatory correspondence tracking,
  • Document requests management,
  • Preparing structured factual responses,
  • Coordinating technical and legal inputs, and
  • Monitoring the progress of the application.

Hearing preparation

Where a personal hearing is required, Corpseed can help organise:

  • Case chronology,
  • Licence history,
  • Technical explanations,
  • Corrective and preventive action,
  • Supporting evidence, and
  • Responses to regulatory observations.

Legal opinions and representation before courts or authorities should be undertaken through appropriately qualified legal professionals where required.

Post-order compliance

Corpseed can support businesses in:

  • Tracking the payment due within 30 days,
  • Maintaining the payment history,
  • Submitting the payment proof,
  • Maintaining the immunity conditions,
  • Ensure ongoing compliance, and
  • Make a regulatory closure document.

Preventive pharmaceutical regulatory compliance services

Apart from the application process, Corpseed can provide help in:

  • Drug license compliance services,
  • CDSCO regulatory advisory,
  • Cosmetic compliance services,
  • Medical device regulatory compliance,
  • Documentation audit,
  • License mapping,
  • Labelling and record audit, and
  • Compliance SOPs.

Need assistance with a CDSCO Rule 4 compounding application? Get free consultation from Corpseed. We can help assess eligibility, identify the competent authority, organise supporting documents and coordinate the compliance process for pharmaceutical, cosmetic and medical-device businesses.

Document Preview

Embedded reference document

Fullscreen ↗

Related

Explore more updates from the same department.

Call